Premium
Antiretroviral drug resistance among antiretroviral‐naïve persons with recent HIV infection in Thailand
Author(s) -
Apisarnthanarak A,
Jirayasethpong T,
Sanguansilp C,
Thongprapai H,
Kittihanukul C,
Kamudamas A,
Tungsathapornpong A,
Mundy LM
Publication year - 2008
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/j.1468-1293.2008.00562.x
Subject(s) - medicine , nevirapine , lamivudine , stavudine , human immunodeficiency virus (hiv) , hiv drug resistance , drug resistance , viral load , antiretroviral therapy , virology , hepatitis b virus , virus , microbiology and biotechnology , biology
Objectives To evaluate the prevalence and patterns of antiretroviral (ARV) drug resistance (ARV‐DR) among ARV drug‐naïve, recently infected persons with HIV in the 4‐year interval (2003–2006) after the inception of the National Access to ARV Programme for People who have AIDS in Thailand. Methods Cross‐sectional study of patients with recent HIV infection for HIV risks, ARV‐DR risks and baseline ARV‐DR. Results Seven of the 305 patients (2%) had baseline ARV‐DR. Via contract tracing, all seven patients with transmitted ARV‐DR identified sexual partners with prior ARV treatment failure and had documented low (<75%) ARV adherence. Annual ARV‐DR increased from 0 to 5.2% ( P= 0.06) between 2003 and 2006. Conclusions Report of sexual partners with potential HIV and ARV drug exposures can prompt baseline ARV‐DR testing of at‐risk individuals, while behavioural interventions for adherence and safer sex are refined to minimize the emergence of resistance to generic, fixed‐dose combination stavudine, lamivudine and nevirapine (GPO‐VIR) therapy.